Dr. John Cush RheumNow
2 years 10 months ago
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Dr. John Cush RheumNow
2 years 10 months ago
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq
Dr. John Cush RheumNow
2 years 10 months ago
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Dr. John Cush RheumNow
2 years 10 months ago
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zjXyldwlyl https://t.co/CpQ00745c1
Dr. John Cush RheumNow
2 years 10 months ago
#PMR: Is There Hidden GCA?
Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA?
https://t.co/Cd6u2GwJuo
@anisha_dua https://t.co/dWUH4zudPc
Dr. John Cush RheumNow
2 years 10 months ago
UK researchers develop a human vascularised synovium-on-a-chip: mechanically stimulated, 3D, microfluidic device w/ synovial cells and blood vessel cells to investigate syn inflammation & monocyte recruitment, mimics the forces applied w/ joint movement https://t.co/qlRHSE3o2b https://t.co/dsKvcsyysa
Dr. John Cush RheumNow
2 years 10 months ago
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/q6aqtcaTxS https://t.co/uZSgoYuxJT
Dr. John Cush RheumNow
2 years 10 months ago
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation? QD Clinics are video vignettes with lessons from the clinic.
https://t.co/YhTkKpmzIl
@sattuiSEMD https://t.co/FTsz3QA5Cn
Dr. John Cush RheumNow
2 years 10 months ago
IL-6 Inhibitors in #PMR: Give early or late?
https://t.co/tMdriuFPYB https://t.co/WMhuogIMJC
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates; Shoulders>Pelvic ~50% have distal MSK Sxs - US: look for B/L sub-acromial/deltoid bursitis https://t.co/GJDGjOD7oX
Dr. John Cush RheumNow
2 years 10 months ago
Draw Your Arthralgias
Featuring Dr. David Liew (Melbourne, Australia)
54 yr old with polyarthralgias, & slightly abnormal labs; could this be #PMR?
https://t.co/siP6Kv1Z1X https://t.co/cMy5ZTybUn
Dr. John Cush RheumNow
2 years 10 months ago
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/yt2GtawuDp https://t.co/FUMFnIXFkk
Dr. John Cush RheumNow
2 years 10 months ago
Surprising Link Between Weight Gain and RA Activity
In patients with RA treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.
https://t.co/hXuJbwiY7B https://t.co/G88CTkSlB5
